Identification

Name
Sulodexide
Accession Number
DB06271
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Thrombolytic agents
Description

Sulodexide is a mixture of glycosaminoglycans (GAGs) composed of dermatan sulfate (DS) and fast moving heparin (FMH).

Protein chemical formula
Not Available
Protein average weight
6500.0 Da (range 5000-8000)
Sequences
Not Available
Synonyms
Not Available
External IDs
KRX-101
International/Other Brands
Sulonex / Vessel
Categories
UNII
75HGV0062C
CAS number
57821-29-1

Pharmacology

Indication

Sulodexide has been used clinically for the prophylaxis and treatment of vascular diseases with increased risk of thrombosis, including intermittent claudication, peripheral arterial occlusive disease and post-myocardial infarc-tion. Also investigated in the treatment of diabetic kidney disease and diabetic neuropathy. New anti-inflammatory properties have also extended its use in venous disease.

Structured Indications
Not Available
Pharmacodynamics

The low molecular weight of both sulodexide fractions allows for extensive oral absorption compared to unfractionated heparin. The pharmacological effects of sulodexide differ substantially from other glycosaminoglycans and are mainly characterized by a prolonged half-life and reduced effect on global coagulation and bleeding parameters. Due to the presence of both glycosaminoglycan fractions, sulodexide potentiates the antiprotease activities of both antithrombin III and heparin cofactor II simultaneously. It is capable of inhibiting both anti-IIa and anti-Xa. It promotes fibrinolytic activity by releasing tissue plasminogen activator and reduces plasminogen activator inhibitor. The drug also blocks platelet adhesion and platelet function induced by cathepsin G and thrombin. Research has also shown that Sulodexide had endothelial protective properties by inducing the overexpression of growth factors important for the protection of organs. It has anti-inflammatory properties via its effect on the release of inflammatory mediators from macrophages. This results in anti-proliferative effects such as the regulation of growth factors like VEGF and FGF. The intravenous administration has also been shown capable of releasing tissue factor pathway inhibitor from the endothelium, which also contributes to the anti-thrombotic effects of Sulodexide. Lastly, this drug is known for its ability to inhibit the secretion of MMPs, particularly MMP-9, from leukocytes in a dose dependent manner, resulting in the restoration of the balance with their tissue inhibitors.

Mechanism of action

Thrombin inhibition produced by sulodexide is due to the additive effect of its components, namely, heparin cofactor II (HCII) catalysis by dermatan sulfate and antithrombin-III catalysis by fast moving heparin (FMH).

TargetActionsOrganism
AHeparin cofactor 2
agonist
Human
AAntithrombin-III
potentiator
Human
Absorption

Sulodexide can be administered via the oral route, IV and IM routes. After oral dosing, the absorption rate being equivalent, the bioavailability is 40-60%. either calculated from the fast-moving heparin fraction or from the dermatan fraction. Bioavailability following IM administration is approximately 90%. After a rapid absorption in the intestine, the dermatan and heparin components start to appear in the plasma. Sulodexide is degraded after ingestion and loses its sulfate groups and both sulfated and unsulfated groups circulate in the blood for up to 24hours. AUC=22.83+/-4.44mg.h/L.

Volume of distribution

Cmax=516+/-77.54ng/mL, Tmax=1.33+/-0.58h, Vd=71.24+/-14.06L (b phase). Sulodexide reaches high concentrations in the plasma and is widely distributed in the endothelial layer. Binding to endothelial cell receptors in arteries and veins contributes to its rapid distribution profile.

Protein binding
Not Available
Metabolism

It is mainly metabolized in the liver.

Route of elimination

Sulodexide is eliminated via the renal, fecal and bile routes. The main clearance occurs renally and accounts for elimination of 55+2.9% of the drug over 96 hours. The fecal and bile routes remove the rest of the drug over 48 hours, which accounts for 23.5+/-2.5% for both routes.

Half life

The elimination half-life was 11.7 +/- 2.0 h after intravenous administration, 18.7 +/- 4.1 h after 50 mg per os, and 25.8 +/- 1.9 h after 100 mg per os.

Clearance

2.70+/-0.58L/h

Toxicity

Sulodexide seems to be well tolerated. Most adverse effects reported are related to the GI system and seem to be transient in nature. Among others adverse reactions are diarrhea, epigastralgia, dyspepsia, heartburn and dizziness. Allergic reactions, such as skin rash, have also been reported but are very rare.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneLimonene, (+)- may increase the anticoagulant activities of Sulodexide.Investigational
AbciximabAbciximab may increase the anticoagulant activities of Sulodexide.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Sulodexide.Approved, Investigational
AcemetacinThe risk or severity of bleeding can be increased when Sulodexide is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Sulodexide.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Sulodexide.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Sulodexide.Approved, Withdrawn
AllylestrenolThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Sulodexide.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Sulodexide.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Sulodexide.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Sulodexide.Approved
AltrenogestThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Altrenogest.Vet Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Sulodexide.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Sulodexide.Approved
AncrodAncrod may increase the anticoagulant activities of Sulodexide.Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Sulodexide.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Sulodexide.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Sulodexide.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Sulodexide.Approved
Antithrombin III humanSulodexide may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Sulodexide.Approved
ApocyninApocynin may increase the anticoagulant activities of Sulodexide.Investigational
ApremilastApremilast may increase the anticoagulant activities of Sulodexide.Approved, Investigational
AprotininThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinArdeparin may increase the anticoagulant activities of Sulodexide.Approved, Investigational, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Sulodexide.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Aripiprazole.Approved, Investigational
Arsenic trioxideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Asenapine.Approved
AstaxanthinAstaxanthin may increase the anticoagulant activities of Sulodexide.Investigational
AtazanavirThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Atazanavir.Approved, Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Sulodexide.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Sulodexide.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Sulodexide.Experimental
BecaplerminBecaplermin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Sulodexide.Experimental
BendroflumethiazideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Bendroflumethiazide.Approved
BenorilateBenorilate may increase the anticoagulant activities of Sulodexide.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Sulodexide.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Sulodexide.Approved
BeraprostBeraprost may increase the anticoagulant activities of Sulodexide.Investigational
BetamethasoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BevoniumBevonium may increase the anticoagulant activities of Sulodexide.Experimental
BivalirudinBivalirudin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
BrexpiprazoleThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Brexpiprazole.Approved
BrinaseBrinase may increase the anticoagulant activities of Sulodexide.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Sulodexide.Approved
BucillamineBucillamine may increase the anticoagulant activities of Sulodexide.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Sulodexide.Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Sulodexide.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Sulodexide.Experimental
BumetanideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Bumetanide.Approved
BuserelinThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Buserelin.Approved
ButylphthalideButylphthalide may increase the anticoagulant activities of Sulodexide.Investigational
CangrelorCangrelor may increase the anticoagulant activities of Sulodexide.Approved
CaplacizumabCaplacizumab may increase the anticoagulant activities of Sulodexide.Investigational
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Sulodexide.Experimental, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Sulodexide.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
CeritinibThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Ceritinib.Approved
CertoparinSulodexide may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineChloroquine may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Sulodexide.Investigational, Withdrawn
ChlorpropamideSulodexide may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Chlorthalidone.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Sulodexide.Approved
CilostazolCilostazol may increase the anticoagulant activities of Sulodexide.Approved
Citric AcidCitric Acid may increase the anticoagulant activities of Sulodexide.Approved, Nutraceutical, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Sulodexide.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Sulodexide.Approved
CloricromenCloricromen may increase the anticoagulant activities of Sulodexide.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Sulodexide.Experimental
ClozapineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Clozapine.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Sulodexide is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensConjugated estrogens may decrease the anticoagulant activities of Sulodexide.Approved
CorticotropinThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Cortisone acetate.Approved
CurcuminCurcumin may increase the anticoagulant activities of Sulodexide.Investigational
CyclopenthiazideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Cyclopenthiazide.Experimental
Cyproterone acetateThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateSulodexide may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Dabrafenib.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Sulodexide.Experimental
DalteparinSulodexide may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSulodexide may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DanazolThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Danazol.Approved
DarexabanSulodexide may increase the anticoagulant activities of Darexaban.Investigational
DarunavirThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Darunavir.Approved
DasatinibDasatinib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Sulodexide is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
DemegestoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Demegestone.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Sulodexide is combined with Deoxycholic Acid.Approved
DersalazineDersalazine may increase the anticoagulant activities of Sulodexide.Investigational
DesirudinSulodexide may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Sulodexide.Investigational
DesogestrelThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Desogestrel.Approved
DexamethasoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DextranSulodexide may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Sulodexide may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Sulodexide may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Sulodexide may increase the anticoagulant activities of Dextran 75.Approved
DiazoxideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Diazoxide.Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Sulodexide.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Sulodexide.Approved, Investigational
DienogestThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Sulodexide.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Sulodexide.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Sulodexide.Approved
DiphenadioneDiphenadione may increase the anticoagulant activities of Sulodexide.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Sulodexide.Approved
DisopyramideSulodexide may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleDitazole may increase the anticoagulant activities of Sulodexide.Approved, Withdrawn
DrospirenoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Sulodexide.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Sulodexide.Withdrawn
DuvelisibDuvelisib may increase the anticoagulant activities of Sulodexide.Investigational
DydrogesteroneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
E-6201E-6201 may increase the anticoagulant activities of Sulodexide.Investigational
Edetic AcidEdetic Acid may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Sulodexide.Approved
EnoxaparinEnoxaparin may increase the anticoagulant activities of Sulodexide.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Sulodexide.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
EpinephrineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EpirizoleEpirizole may increase the anticoagulant activities of Sulodexide.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Sulodexide.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Sulodexide.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Sulodexide.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Sulodexide.Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Sulodexide.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Sulodexide.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease the anticoagulant activities of Sulodexide.Approved
EstroneEstrone may decrease the anticoagulant activities of Sulodexide.Approved
Estrone sulfateThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Etacrynic acid.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Sulodexide.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Sulodexide.Experimental
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Sulodexide.Approved
Ethyl biscoumacetateSulodexide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Ethynodiol diacetate.Approved
EtodolacEtodolac may increase the anticoagulant activities of Sulodexide.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Sulodexide.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Sulodexide.Approved, Investigational
EverolimusThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Everolimus.Approved
ExisulindExisulind may increase the anticoagulant activities of Sulodexide.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Sulodexide.Experimental
FenbufenFenbufen may increase the anticoagulant activities of Sulodexide.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Sulodexide.Approved
FentiazacFentiazac may increase the anticoagulant activities of Sulodexide.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Sulodexide.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Sulodexide.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Sulodexide.Investigational
FloctafenineFloctafenine may increase the anticoagulant activities of Sulodexide.Approved, Withdrawn
FludrocortisoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Fludrocortisone.Approved
FluindioneSulodexide may increase the anticoagulant activities of Fluindione.Investigational
FlunixinFlunixin may increase the anticoagulant activities of Sulodexide.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Sulodexide.Experimental
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
FondaparinuxSulodexide may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Sulodexide.Approved, Investigational
FosamprenavirThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Fosamprenavir.Approved
FurosemideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Furosemide.Approved, Vet Approved
GabexateSulodexide may increase the anticoagulant activities of Gabexate.Investigational
GenisteinGenistein may decrease the anticoagulant activities of Sulodexide.Investigational
GestodeneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Gestrinone.Approved
GliclazideSulodexide may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideSulodexide may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideSulodexide may increase the hypoglycemic activities of Glipizide.Approved
GlyburideSulodexide may increase the hypoglycemic activities of Glyburide.Approved
GoserelinThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Goserelin.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Sulodexide.Experimental
HeminHemin may increase the anticoagulant activities of Sulodexide.Approved
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Sulodexide.Experimental
HeparinHeparin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Sulodexide.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Sulodexide.Investigational
HistrelinThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Histrelin.Approved
HydrochlorothiazideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Sulodexide.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Sulodexide is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Sulodexide.Approved
IbudilastIbudilast may increase the anticoagulant activities of Sulodexide.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Sulodexide.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Sulodexide.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Sulodexide.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Sulodexide.Approved, Nutraceutical
IdraparinuxSulodexide may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Sulodexide.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Sulodexide.Investigational
IloperidoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Iloperidone.Approved
IloprostIloprost may increase the anticoagulant activities of Sulodexide.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Sulodexide.Experimental
IndapamideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Indapamide.Approved
IndinavirThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Indinavir.Approved
IndobufenIndobufen may increase the anticoagulant activities of Sulodexide.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Sulodexide.Withdrawn
Insulin AspartSulodexide may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirSulodexide may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineSulodexide may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineSulodexide may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanSulodexide may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproSulodexide may increase the hypoglycemic activities of Insulin Lispro.Approved
IsoxicamIsoxicam may increase the anticoagulant activities of Sulodexide.Withdrawn
KebuzoneKebuzone may increase the anticoagulant activities of Sulodexide.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Sulodexide.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Sulodexide.Approved
LanreotideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Lanreotide.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Sulodexide.Approved
LetaxabanSulodexide may increase the anticoagulant activities of Letaxaban.Investigational
LeuprolideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Leuprolide.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Sulodexide.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Sulodexide.Experimental
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Sulodexide.Approved, Nutraceutical
LisofyllineLisofylline may increase the anticoagulant activities of Sulodexide.Investigational
LonazolacLonazolac may increase the anticoagulant activities of Sulodexide.Experimental
LopinavirThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Lopinavir.Approved
LornoxicamLornoxicam may increase the anticoagulant activities of Sulodexide.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
LumiracoxibLumiracoxib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
LurasidoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Lurasidone.Approved
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Sulodexide.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Sulodexide.Approved, Investigational
MecaserminSulodexide may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
MedrogestoneThe serum concentration of Sulodexide can be decreased when it is combined with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Sulodexide.Approved
Megestrol acetateThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MelagatranSulodexide may increase the anticoagulant activities of Melagatran.Experimental
MeloxicamMeloxicam may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Sulodexide.Approved
MestranolMestranol may decrease the anticoagulant activities of Sulodexide.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Sulodexide.Investigational, Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Sulodexide.Experimental
MethotrimeprazineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Methotrimeprazine.Approved
MethyclothiazideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Methyclothiazide.Approved
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
MethylestrenoloneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Methylestrenolone.Experimental
MethylprednisoloneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MetolazoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Metolazone.Approved
MifepristoneSulodexide may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Sulodexide.Approved
MizoribineMizoribine may increase the anticoagulant activities of Sulodexide.Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Sulodexide.Experimental
MoxestrolMoxestrol may decrease the anticoagulant activities of Sulodexide.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Sulodexide.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Sulodexide.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Sulodexide.Approved
NadroparinSulodexide may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNafamostat may increase the anticoagulant activities of Sulodexide.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Sulodexide.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Sulodexide.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
NateglinideSulodexide may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NelfinavirThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Nelfinavir.Approved
NepafenacNepafenac may increase the anticoagulant activities of Sulodexide.Approved
NiacinThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NifenazoneNifenazone may increase the anticoagulant activities of Sulodexide.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Sulodexide.Approved
NilotinibThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the anticoagulant activities of Sulodexide.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Sulodexide is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Sulodexide.Investigational
NomegestrolThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Norethisterone.Approved
NorgestimateThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Norgestimate.Approved
NorgestrienoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Norgestrienone.Experimental
ObinutuzumabThe risk or severity of adverse effects can be increased when Sulodexide is combined with Obinutuzumab.Approved
OctreotideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Octreotide.Approved, Investigational
OlanzapineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Olanzapine.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Sulodexide.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Sulodexide.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Sulodexide is combined with Omacetaxine mepesuccinate.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Sulodexide.Approved, Nutraceutical
OrgoteinOrgotein may increase the anticoagulant activities of Sulodexide.Vet Approved
OtamixabanSulodexide may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Sulodexide.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Sulodexide.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Sulodexide.Investigational
PaliperidoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Paliperidone.Approved
ParecoxibParecoxib may increase the anticoagulant activities of Sulodexide.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Sulodexide.Investigational
PasireotideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Pasireotide.Approved
Pentaerythritol TetranitratePentaerythritol Tetranitrate may increase the anticoagulant activities of Sulodexide.Approved
PentamidineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Pentamidine.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Sulodexide.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Sulodexide.Approved, Investigational
PhenindionePhenindione may increase the anticoagulant activities of Sulodexide.Approved, Investigational
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Sulodexide.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Sulodexide.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Sulodexide.Approved, Investigational
PiperazineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Pipotiazine.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Sulodexide.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Sulodexide.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Sulodexide.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Sulodexide.Approved
PolythiazideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Polythiazide.Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Sulodexide.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Sulodexide.Approved
PrednisoloneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of heart failure can be increased when Pregabalin is combined with Sulodexide.Approved, Illicit, Investigational
ProgesteroneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Sulodexide.Experimental
PromegestoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Sulodexide.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Sulodexide.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Sulodexide.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Sulodexide.Experimental
Protein CSulodexide may increase the anticoagulant activities of Protein C.Approved
Protein S humanSulodexide may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSulodexide may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299PTC299 may increase the anticoagulant activities of Sulodexide.Investigational
QuetiapineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Quetiapine.Approved
QuinestrolQuinestrol may decrease the anticoagulant activities of Sulodexide.Approved
QuinethazoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Quinethazone.Approved
QuinineSulodexide may increase the hypoglycemic activities of Quinine.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Sulodexide.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Sulodexide.Investigational
RepaglinideSulodexide may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Sulodexide.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Sulodexide.Approved
ReviparinSulodexide may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Sulodexide.Approved
RisperidoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Risperidone.Approved, Investigational
RitonavirThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Ritonavir.Approved, Investigational
RivaroxabanSulodexide may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Sulodexide.Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SalicylamideSalicylamide may increase the anticoagulant activities of Sulodexide.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Sulodexide.Approved
SaquinavirThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Saquinavir.Approved, Investigational
SarpogrelateSarpogrelate may increase the anticoagulant activities of Sulodexide.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Sulodexide.Experimental
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Sulodexide.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Sulodexide.Approved
SemapimodSemapimod may increase the anticoagulant activities of Sulodexide.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Sulodexide.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Sulodexide.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
SirolimusThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Sirolimus.Approved, Investigational
SRT501SRT501 may increase the anticoagulant activities of Sulodexide.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Sulodexide.Approved
SulfadiazineSulodexide may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulodexide may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Sulodexide.Approved
SulfisoxazoleSulodexide may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the anticoagulant activities of Sulodexide.Approved
SunitinibSulodexide may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Sulodexide.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Sulodexide.Experimental
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Sulodexide.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Sulodexide.Approved
TacrolimusThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Tacrolimus.Approved, Investigational
TarenflurbilTarenflurbil may increase the anticoagulant activities of Sulodexide.Investigational
TemsirolimusThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Temsirolimus.Approved
TenecteplaseTenecteplase may increase the anticoagulant activities of Sulodexide.Approved
TenidapTenidap may increase the anticoagulant activities of Sulodexide.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Sulodexide.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Sulodexide.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Sulodexide.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Sulodexide.Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Sulodexide.Approved
TiboloneTibolone may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Sulodexide.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Sulodexide.Approved
TinoridineTinoridine may increase the anticoagulant activities of Sulodexide.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Sulodexide.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Sulodexide.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Sulodexide.Approved
TolazamideSulodexide may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideSulodexide may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Sulodexide.Approved
TolmetinTolmetin may increase the anticoagulant activities of Sulodexide.Approved
TorasemideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Torasemide.Approved
TositumomabThe risk or severity of adverse effects can be increased when Sulodexide is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Sulodexide.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TriamcinoloneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TribenosideTribenoside may increase the anticoagulant activities of Sulodexide.Experimental
TrichlormethiazideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TriflusalTriflusal may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TriptolideTriptolide may increase the anticoagulant activities of Sulodexide.Investigational
TriptorelinThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Triptorelin.Approved, Vet Approved
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Sulodexide.Approved
TroxerutinSulodexide may increase the anticoagulant activities of Troxerutin.Investigational
UbidecarenoneThe therapeutic efficacy of Sulodexide can be increased when used in combination with Ubidecarenone.Approved, Investigational, Nutraceutical
UrokinaseUrokinase may increase the anticoagulant activities of Sulodexide.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Sulodexide.Investigational, Withdrawn
Vitamin EVitamin E may increase the anticoagulant activities of Sulodexide.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Sulodexide.Approved
VorinostatThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Vorinostat.Approved, Investigational
WarfarinWarfarin may increase the anticoagulant activities of Sulodexide.Approved
XimelagatranXimelagatran may increase the anticoagulant activities of Sulodexide.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Sulodexide.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Sulodexide.Approved, Investigational, Withdrawn
ZiprasidoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Ziprasidone.Approved
ZomepiracZomepirac may increase the anticoagulant activities of Sulodexide.Withdrawn
Food Interactions
Not Available

References

General References
  1. Cosmi B, Cini M, Legnani C, Pancani C, Calanni F, Coccheri S: Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. Thromb Res. 2003 Mar 15;109(5-6):333-9. [PubMed:12818259]
  2. Harenberg J: Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998 Jan;18(1):1-20. [PubMed:9436179]
  3. Lasierra-Cirujeda J, Coronel P, Aza M, Gimeno M: Use of sulodexide in patients with peripheral vascular disease. J Blood Med. 2010;1:105-15. doi: 10.2147/JBM.S10558. Epub 2010 Jun 15. [PubMed:22282689]
  4. Hoppensteadt DA, Fareed J: Pharmacological profile of sulodexide. Int Angiol. 2014 Jun;33(3):229-35. [PubMed:24936531]
External Links
KEGG Drug
D08547
PubChem Substance
347910343
ChEMBL
CHEMBL2108086
Therapeutic Targets Database
DAP000866
PharmGKB
PA164746343
Wikipedia
Sulodexide
ATC Codes
B01AB11 — Sulodexide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1WithdrawnPreventionDense Deposit Disease1
2CompletedTreatmentRetinopathy, Diabetic1
2CompletedTreatmentTinnitus, Subjective1
3CompletedTreatmentDiabetic Nephropathies1
3Not Yet RecruitingTreatmentPeripheral Arterial Obstructive Disease1
3TerminatedTreatmentDiabetic Nephropathies1
3Unknown StatusTreatmentChronic Kidney Disease (CKD)1
4TerminatedOtherPost-Thrombotic Syndrome1
4TerminatedTreatmentDiabetic Nephropathies1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Serine-type endopeptidase inhibitor activity
Specific Function
Thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT...
Gene Name
SERPIND1
Uniprot ID
P05546
Uniprot Name
Heparin cofactor 2
Molecular Weight
57070.16 Da
References
  1. Cosmi B, Cini M, Legnani C, Pancani C, Calanni F, Coccheri S: Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. Thromb Res. 2003 Mar 15;109(5-6):333-9. [PubMed:12818259]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Serine-type endopeptidase inhibitor activity
Specific Function
Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory a...
Gene Name
SERPINC1
Uniprot ID
P01008
Uniprot Name
Antithrombin-III
Molecular Weight
52601.935 Da
References
  1. Cosmi B, Cini M, Legnani C, Pancani C, Calanni F, Coccheri S: Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. Thromb Res. 2003 Mar 15;109(5-6):333-9. [PubMed:12818259]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. Harenberg J: Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998 Jan;18(1):1-20. [PubMed:9436179]

Drug created on March 19, 2008 10:20 / Updated on November 06, 2017 06:45